End-of-day quote
Korea S.E.
23:00:00 15/05/2024 BST
5-day change
1st Jan Change
11,670
KRW
-0.51%
-2.75%
-12.12%
05-02
Gemvaxlink Co., Ltd. announced that it has received KRW 39.0999772 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd
CI
03-25
GemVax&KAEL Co.,Ltd. announced that it has received KRW 17.6 billion in funding from Kiwoom Asset Management Co., Ltd., J&J Assets Management Ltd., Youngjin Industry Co., Ltd. and other investors
CI
GemVax&KAEL Co.,Ltd authorizes a Buyback Plan.
The Board of Directors of GemVax&KAEL Co.,Ltd has authorized a buyback plan on June 14, 2022.
Gemvaxlink Co., Ltd. announced that it has received KRW 39.0999772 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd
05-01
CI
GemVax&KAEL Co.,Ltd. announced that it has received KRW 17.6 billion in funding from Kiwoom Asset Management Co., Ltd., J&J Assets Management Ltd., Youngjin Industry Co., Ltd. and other investors
03-24
CI
GemVax&KAEL Co.,Ltd. announced that it expects to receive KRW 17.6 billion in funding from Kiwoom Asset Management Co., Ltd., J&J Assets Management Ltd., Youngjin Industry Co., Ltd. and other investors
03-20
CI
Gemvaxlink Co., Ltd. announced that it has received KRW 29.099978456 billion in funding from GemVax&KAEL Co.,Ltd., Keonyang Co., Ltd., Wingbridge I&D Co., Ltd., Kaffaint Co. Ltd and other investors
03-17
CI
Tranche Update on GemVax&KAEL Co.,Ltd's Equity Buyback Plan announced on June 14, 2022.
31/08/22
CI
GemVax&KAEL Co.,Ltd announces an Equity Buyback for 150,000 shares.
14/06/22
CI
GemVax&KAEL Co.,Ltd authorizes a Buyback Plan.
13/06/22
CI
Tranche Update on GemVax&KAEL Co.,Ltd's Equity Buyback Plan announced on April 13, 2022.
13/06/22
CI
GemVax&KAEL Co.,Ltd's Equity Buyback announced on April 13, 2022, has closed with 300,000 shares, representing 0.76% for KRW 4,333.75 million.
09/06/22
CI
GemVax&KAEL Co.,Ltd announces an Equity Buyback for 300,000 shares.
13/04/22
CI
GemVax&KAEL Co.,Ltd authorizes a Buyback Plan.
12/04/22
CI
GemVax&KAEL Co.,Ltd(KOSDAQ:A082270) added to S&P Global BMI Index
20/09/21
CI
GemVax&KAEL Co.,Ltd acquired additional 12.9% stake in Gemvaxlink Co., Ltd. for KRW 18 billion.
18/08/21
CI
GemVax&KAEL Co.,Ltd acquired additional 12.99% stake in Gemvaxzio Co., Ltd. for KRW 18.02 billion.
18/08/21
CI
GemVax's Highly Promising Phase II Alzheimer's Disease Clinical Trial Results Targeting Telomerase Published in Alzheimer's Research & Therapy' Journal
30/03/21
CI
GemVax&KAEL Co.,Ltd(KOSDAQ:A082270) dropped from S&P Global BMI Index
22/03/21
CI
GemVax & KAEL Announces the Decision to Apply for an Expanded Access IND for Its Lead Candidate GV1001 to Include Additional Investigational Groups in Alzheimer's
06/10/20
CI
Gemvaxzio Co., Ltd. announced that it has received KRW 3.49999944 billion in funding from GemVax&KAEL Co.,Ltd
17/06/20
CI
Gemvaxzio Co., Ltd. announced that it expects to receive KRW 3.49999944 billion in funding from GemVax&KAEL Co.,Ltd
09/06/20
CI
Gemvaxzio Co., Ltd. announced that it has received KRW 4.999999927 billion in funding from GemVax&KAEL Co.,Ltd
15/04/20
CI
Gemvaxzio Co., Ltd. announced that it expects to receive KRW 4.999999927 billion in funding from GemVax&KAEL Co.,Ltd
07/04/20
CI
Gemvaxzio Co., Ltd. announced that it has received KRW 8.4 billion in funding from GemVax&KAEL Co.,Ltd
29/03/20
CI
GemVax Announces Phase II Results of GV1001 for Alzheimer's Disease Treatment at CTAD 2019
11/12/19
CI
Enerzent Co., Ltd. announced that it has received KRW 10 billion in funding from GemVax&KAEL Co.,Ltd
10/02/19
CI
GemVax&KAEL Co.,Ltd announced that it has received KRW 35 billion in funding
09/08/18
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
GemVax & KAEL Co.,Ltd is a Korea-based company mainly engaged in the manufacture of pollution control equipment used in semiconductor manufacturing processes. The Company and its subsidiaries are engaged in the three categories of businesses: pollution control business, which manufactures chemical air (CA) filters, gas scrubbers, resins, coating resins and other environmental equipments and systems; anticancer and anti-inflammation business, which engages in development of cancer vaccines for infectious diseases, such as acquired immune deficiency syndrome (AIDS) and anti-inflammations, and IT business which mainly produces liquid crystal display (LCD) modules. The Company distributes its products within domestic market and to overseas markets.
More about the company
1st Jan change
Capi.
-12.12% 342M +90.67% 2,328B +41.82% 677B +28.26% 666B +11.90% 258B +34.68% 217B +14.55% 178B +50.83% 142B -36.52% 133B +52.13% 118B
Other Semiconductors
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1